Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 132.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,815 shares of the company's stock after buying an additional 14,157 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd's holdings in Twist Bioscience were worth $1,153,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of TWST. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience during the 3rd quarter valued at $34,000. Van ECK Associates Corp grew its position in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after buying an additional 267 shares during the period. US Bancorp DE increased its holdings in shares of Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after acquiring an additional 601 shares in the last quarter. Beaird Harris Wealth Management LLC acquired a new position in Twist Bioscience in the 3rd quarter worth $95,000. Finally, KBC Group NV raised its holdings in shares of Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after purchasing an additional 1,226 shares during the last quarter.

Twist Bioscience Stock Up 3.0 %

TWST stock traded up $1.19 on Tuesday, reaching $40.45. 271,111 shares of the company traded hands, compared to its average volume of 939,240. The firm has a fifty day simple moving average of $44.99 and a 200-day simple moving average of $45.33. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The company has a market cap of $2.41 billion, a P/E ratio of -11.96 and a beta of 2.15.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million for the quarter, compared to analysts' expectations of $86.96 million. During the same quarter in the previous year, the company earned ($0.75) EPS. Twist Bioscience's revenue for the quarter was up 24.1% on a year-over-year basis. Research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, COO Patrick John Finn sold 2,422 shares of the business's stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $50.17, for a total value of $121,511.74. Following the completion of the transaction, the chief operating officer now directly owns 272,044 shares of the company's stock, valued at approximately $13,648,447.48. The trade was a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert Chess sold 2,940 shares of the business's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the sale, the director now directly owns 18,173 shares of the company's stock, valued at approximately $965,531.49. The trade was a 13.93 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,799 shares of company stock valued at $1,593,944. Company insiders own 3.01% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Robert W. Baird lifted their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 target price on the stock. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the company an "overweight" rating in a research note on Monday, February 3rd. Finally, JPMorgan Chase & Co. increased their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $54.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.